List of Excipients in Branded Drug VIZIMPRO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	VIZIMPRO	dacomitinib	0069-0197	CELLULOSE, MICROCRYSTALLINE	2032-09-27
Pfizer Laboratories Div Pfizer Inc	VIZIMPRO	dacomitinib	0069-0197	FD&C BLUE NO. 2	2032-09-27
Pfizer Laboratories Div Pfizer Inc	VIZIMPRO	dacomitinib	0069-0197	LACTOSE MONOHYDRATE	2032-09-27
Pfizer Laboratories Div Pfizer Inc	VIZIMPRO	dacomitinib	0069-0197	MAGNESIUM STEARATE	2032-09-27
Pfizer Laboratories Div Pfizer Inc	VIZIMPRO	dacomitinib	0069-0197	POLYETHYLENE GLYCOL 3350	2032-09-27

Vizimpro (Dacomitinib) Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

Vizimpro is an oral, film-coated dacomitinib tablet approved for metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations. Its excipient opportunity is primarily a generic-formulation and supply-chain opportunity, not a biologic or complex-delivery opportunity. The commercial priorities are excipient equivalence, tablet robustness, film-coat reproducibility, lactose management, and a low-cost platform supporting 15 mg, 30 mg, and 45 mg strengths.

The reference product uses a conventional immediate-release tablet architecture. FDA labeling identifies lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate in the tablet core. The film coating contains standard coating materials and colorants, although the US prescribing information does not disclose quantitative excipient levels.[1]

What is Vizimpro and how does its dosage form affect excipient strategy?

Vizimpro contains dacomitinib, a small-molecule irreversible epidermal growth factor receptor tyrosine kinase inhibitor. The approved dosage is 45 mg orally once daily, with dose reductions to 30 mg and 15 mg for adverse reactions.[1]

Product architecture

Attribute	Vizimpro profile
Active ingredient	Dacomitinib
Therapeutic class	EGFR tyrosine kinase inhibitor
Dosage form	Immediate-release, film-coated tablet
Approved strengths	15 mg, 30 mg, 45 mg
Administration	Once daily, with or without food
Primary indication	EGFR-mutated metastatic NSCLC
Reference sponsor	Pfizer
FDA approval	September 27, 2018
Key excipients disclosed in labeling	Lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, magnesium stearate
Biosimilar pathway	Not applicable; dacomitinib is a small molecule

The formulation does not require a lipid vehicle, injectable excipient, enteric protection, controlled-release polymer, or device-linked delivery system. That reduces technical barriers for an ANDA developer but increases price competition among commodity excipients.

What excipients are used in Vizimpro tablets?

The disclosed core excipients have conventional functional roles.

Excipient	Likely formulation function	Commercial relevance
Lactose monohydrate	Diluent and tablet-bulk agent	Creates an opportunity for lactose-free substitution, but such a change requires formulation and bioequivalence support
Microcrystalline cellulose	Diluent, compression aid, and structural filler	Important for tablet tensile strength and low-dose content uniformity
Sodium starch glycolate	Superdisintegrant	Supports rapid tablet breakup and immediate-release dissolution
Magnesium stearate	Lubricant	Affects ejection force, blend flow, hardness, and dissolution
Film-coat materials	Protection, appearance, swallowability, and product identification	Potential area for colorant, coating-process, and supplier differentiation

The label does not provide excipient quantities, particle-size specifications, grade designations, or manufacturing-process parameters.[1] Those undisclosed variables can materially affect dissolution, tablet strength, friability, and content uniformity.

Formulation risk points

Dacomitinib tablets contain a relatively low drug load compared with the total tablet mass. The formulation therefore depends on blend uniformity and segregation control. Microcrystalline cellulose can support compressibility, while sodium starch glycolate can offset the slower disintegration that may result from higher compression force or excess lubricant.

Magnesium stearate requires tight process control. Excessive concentration or prolonged lubrication can create hydrophobic tablet surfaces and slow dissolution. This is a practical development risk for a generic formulation that changes the grade, mixing time, or lubricant addition sequence.

Lactose offers favorable cost and processing characteristics but may limit positioning for patients seeking lactose-free products. A lactose-free formulation could use mannitol, dibasic calcium phosphate, pregelatinized starch, or an alternative microcrystalline-cellulose system. The opportunity is commercially credible, but the substitute must preserve tablet strength, disintegration, dissolution, stability, and bioequivalence.

What formulation opportunities exist for generic Vizimpro?

The most attractive opportunity is a conventional immediate-release ANDA formulation that uses the reference excipient set or a close functional equivalent.

Q1 and Q2 formulation strategy

A Q1/Q2 approach uses the same inactive ingredients and, generally, the same qualitative and quantitative composition as the reference product. Because the public label does not disclose exact amounts, an applicant would need to characterize the reference product and develop a composition that meets the applicable regulatory standard.

A Q1/Q2 approach can reduce development risk in the following areas:

• Dissolution matching
• Tablet disintegration
• Excipient compatibility
• Scale-up behavior
• Manufacturing-process transfer
• Bioequivalence risk

A Q1/Q2 approach can also reduce commercial differentiation. If several generic manufacturers use comparable lactose, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, and coating systems, competition will shift toward supply reliability, manufacturing cost, launch timing, and contracting strategy.

Lactose-free opportunity

A lactose-free Vizimpro equivalent could target:

• Patients with lactose intolerance
• Hospital formularies with lactose-restricted policies
• Specialty pharmacies seeking differentiated generic products
• International markets where excipient labeling preferences differ

The opportunity is limited by the product's oral tablet format and the absence of a broad consumer-facing brand identity. A lactose-free claim would require a complete reformulation and cannot be inferred solely from use of alternative diluents.

Direct-compression opportunity

A direct-compression process could lower manufacturing complexity if the API and excipient grades provide adequate flow, uniformity, and compactability. Microcrystalline cellulose is well suited to direct compression, but dacomitinib particle properties, blend segregation, and low-dose distribution would determine feasibility.

An alternative wet-granulation process could improve uniformity and flow but would increase equipment, cycle-time, and scale-up costs. The commercial choice depends on the API's bulk density, particle-size distribution, cohesion, and sensitivity to moisture.

Film-coating opportunity

The film coat is unlikely to create a high-value exclusivity position by itself. It can still produce operational and commercial advantages through:

• Faster coating cycles
• Lower coating weight
• Reduced color variability
• Improved abrasion resistance
• Lower solvent or water consumption
• Greater visual distinction between 15 mg, 30 mg, and 45 mg strengths

A coating supplier with ready-to-use aqueous systems, optimized color matching, and validated scale-up support could compete for generic manufacturing contracts. The addressable opportunity is more likely to arise from repeated supply across multiple oncology tablets than from Vizimpro alone.

What FDA regulatory pathway applies to generic Vizimpro?

A generic dacomitinib product would generally use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence to the listed drug, subject to FDA requirements for the product and any applicable reference listed drug designation.[2]

Regulatory priorities for an ANDA formulation

The development package would normally address:

1. Same active ingredient and dosage form.
2. Equivalent strength and route of administration.
3. Comparable quality attributes.
4. In vitro dissolution across relevant media.
5. Bioequivalence under FDA-accepted study conditions.
6. Stability under ICH conditions.
7. Manufacturing-process validation.
8. Excipient safety and regulatory acceptability.

The FDA Inactive Ingredient Database can support excipient selection by showing precedent for particular ingredients, routes, and dosage forms. It does not eliminate the need to assess maximum daily exposure, grade, particle size, functionality, or product-specific performance.[3]

What patent and exclusivity issues affect Vizimpro generic entry?

Vizimpro is a small-molecule product, so biosimilar risk does not apply. Generic entry is governed by small-molecule patent, exclusivity, and ANDA litigation rules.

Paragraph IV challenge

A generic applicant can file a Paragraph IV certification against listed patents that it believes are invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger patent litigation and, in certain circumstances, a 30-month stay of FDA approval under the Hatch-Waxman framework.[2]

The commercial value of an excipient strategy depends on whether the relevant barriers are directed to:

• Dacomitinib composition of matter
• Crystalline or polymorphic forms
• Salt or solvate forms
• Pharmaceutical compositions
• Therapeutic methods
• Manufacturing processes
• Drug combinations

A formulation using different excipients may avoid a narrow composition claim, but it does not avoid a composition-of-matter patent or a method-of-use patent. Conversely, a formulation patent may be irrelevant if the generic applicant can establish noninfringement or invalidity.

Orange Book status

The FDA Orange Book is the controlling public source for listed patents, expiration data, pediatric exclusivity, and reference-product information.[4] Patent status can change through delisting, expiration, litigation outcomes, settlements, or regulatory updates. Commercial launch planning should therefore distinguish:

• Earliest possible approval date
• Earliest noninfringing launch date
• Patent expiration
• Regulatory exclusivity expiration
• Settlement-controlled entry date

No biosimilar pathway or biosimilar substitution framework applies to dacomitinib.

When does Vizimpro lose exclusivity and when can generics launch?

The approval date alone does not establish the generic launch date. Vizimpro was approved in 2018, but commercial entry depends on applicable listed patents, regulatory exclusivity, Paragraph IV activity, and any settlement restrictions.

For a launch model, companies should evaluate the following sequence:

Event	Commercial effect
ANDA submission	Begins regulatory review but does not authorize marketing
Paragraph IV notice	Can trigger patent litigation
Patent litigation	May create a 30-month approval stay
Patent expiration or settlement date	Determines the practical launch window
ANDA approval	Permits marketing only after applicable legal barriers are cleared
First approved Paragraph IV ANDA	May create 180-day exclusivity for a qualifying first applicant

A differentiated excipient formulation does not create an independent right to market before an applicable patent barrier expires.

How strong is the Vizimpro formulation opportunity?

The formulation barrier is moderate to low compared with products using modified release, sterile delivery, complex lipids, or device-dependent administration.

Strengths for generic development

• Conventional oral tablet
• Standard excipient classes
• Three strengths based on one dosage-form platform
• No injection or cold-chain requirement
• No biosimilar comparability program
• No controlled-release technology requirement
• Publicly disclosed core excipient categories

Development barriers

• Low-dose blend uniformity
• Dacomitinib-excipient compatibility
• Dissolution sensitivity to lubrication and compression
• Strength-to-strength manufacturing consistency
• Oncology-product containment and cleaning requirements
• Patent and method-of-use analysis
• Potentially limited commercial volume after generic entry

The technical formulation estate is therefore less likely to block entry than patent timing, demand concentration, and price erosion.

What commercial opportunities exist for excipient suppliers?

The opportunity is strongest for suppliers that can offer validated, multifunctional, or differentiated grades rather than commodity materials alone.

High-potential supplier positions

Direct-compression excipients

Co-processed microcrystalline-cellulose systems, spray-dried lactose, mannitol blends, and multifunctional fillers can reduce manufacturing steps and improve flow. Their value depends on demonstrable improvement in content uniformity, compression, or dissolution.

Superdisintegrants

Low-use-level sodium starch glycolate or alternative superdisintegrants can support rapid disintegration while controlling tablet weight. Suppliers can compete through particle morphology, swelling performance, and consistency across lots.

Lubricant systems

Magnesium stearate with controlled surface area, low moisture, and consistent fatty-acid composition can reduce batch variability. Lubricant optimization is particularly relevant where dissolution is sensitive to over-lubrication.

Film-coat systems

Ready-to-use aqueous coatings can reduce color-matching and process-development work. The strongest opportunity is a platform covering multiple strengths and several oncology products.

Lactose alternatives

Mannitol and calcium-phosphate systems can support lactose-free positioning, but the commercial case depends on whether the finished product earns formulary or patient preference advantages sufficient to offset development cost.

How does Vizimpro compare with other EGFR inhibitors?

Vizimpro has a simpler excipient profile than many extended-release or specialty delivery products, but its clinical and commercial positioning differs from other EGFR inhibitors.

Product	Active ingredient	Dosage form	Excipient complexity	Generic or follow-on relevance
Vizimpro	Dacomitinib	Immediate-release tablet	Conventional	ANDA
Iressa	Gefitinib	Immediate-release tablet	Conventional	ANDA
Tarceva	Erlotinib	Immediate-release tablet	Conventional	ANDA
Tagrisso	Osimertinib	Immediate-release tablet	Conventional	ANDA
Gilotrif	Afatinib	Immediate-release tablet	Conventional	ANDA

The main differentiator for Vizimpro is not delivery technology. It is the interaction between EGFR mutation-specific demand, treatment sequencing, tolerability management, patent timing, and payer behavior.

Key Takeaways

• Vizimpro is a conventional immediate-release dacomitinib film-coated tablet.
• The disclosed core excipients are lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.
• Generic formulation risk centers on low-dose content uniformity, lubrication, dissolution, and scale-up.
• The strongest excipient opportunities are multifunctional direct-compression systems, superdisintegrants, controlled-grade magnesium stearate, aqueous film coats, and lactose alternatives.
• A lactose-free or process-optimized product could differentiate commercially, but it would require full formulation and bioequivalence development.
• Dacomitinib does not create a biosimilar opportunity. Generic companies would use the ANDA pathway.
• Excipient substitution cannot bypass composition-of-matter, method-of-use, or manufacturing patents.
• The commercial launch date depends on current Orange Book listings, Paragraph IV litigation, regulatory exclusivity, and any settlement terms.
• The formulation barrier is moderate to low. Patent timing and post-entry price erosion are likely to determine value more than excipient complexity.

FAQs

Can Vizimpro tablets be reformulated without lactose?

Yes. A generic developer could evaluate mannitol, dibasic calcium phosphate, pregelatinized starch, or alternative cellulose systems. The substitute must support pharmaceutical equivalence, dissolution, stability, and bioequivalence.

Is dacomitinib suitable for an orally disintegrating tablet?

It may be technically feasible, but the commercial rationale is uncertain. Dacomitinib is administered as a conventional swallowed tablet, and an orally disintegrating product would require new taste, moisture, mechanical-strength, and bioequivalence work.

Do excipient changes avoid Vizimpro patents?

Not necessarily. Excipient changes may avoid a narrow formulation claim, but they do not avoid patents covering dacomitinib itself, a protected crystal form, a manufacturing process, or a method of treatment.

Which excipient is most likely to affect dacomitinib dissolution?

Magnesium stearate is a key risk because excess lubrication or prolonged blending can reduce wetting and slow dissolution. Disintegrant level, compression force, and tablet porosity also influence release.

Can one formulation platform support all three Vizimpro strengths?

Potentially. A common excipient platform can support 15 mg, 30 mg, and 45 mg tablets, but each strength requires independent control of content uniformity, weight variation, mechanical properties, dissolution, and stability.

References

1. U.S. Food and Drug Administration. (2018). Vizimpro (dacomitinib) prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database-download

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book